Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria and your genes: a new clue in Alzheimer's puzzle?

NCT ID NCT05905822

Knowledge-focused Sponsor: University of East Anglia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study from the University of East Anglia looked at how gut bacteria break down certain plant compounds (flavan-3-ols) in people with different versions of the APOE gene, which is linked to Alzheimer's risk. 49 healthy adults donated stool and saliva samples. The goal was to see if gene type affects how gut microbes process these compounds, which could help explain why some people are more at risk for Alzheimer's.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dietary plant extracts (flavan-3-ols)
What this could lead to
If successful, this could point toward personalized dietary recommendations to reduce Alzheimer's risk based on a person's genes and gut bacteria.
What could go wrong
This is a small, completed lab study using stool samples, not a treatment trial. It only looks at how bacteria process compounds, not whether those compounds prevent or treat Alzheimer's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

49 people

The number who actually took part.

Started

Jun 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy adults who fit the above inclusion and exclusion criteria. Able to donate a stool and salivary sample.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 18-35 years old or aged 55+ years old * Fluent in written and spoken English and capacity to consent * Availability to take part in the study Exclusion Criteria: * Participants will be excluded from donating if they have been diagnosed with any gastrointestinal conditions such as inflammatory bowel disease. * They will also be excluded if they have a diagnosis of any form of dementia or severe cognitive impairment. * They currently consume a high flavonoid intake defined as \>15 portions of flavonoid rich food per day. * History or MRI evidence of brain damage, including significant trauma, stroke, learning difficulties or serious neurological disorder, including a loss of consciousness for more than 24 hours. * Currently smoking or ceased smoking less than 6 months ago. * Chronic fatigue syndrome, liver disease, diabetes mellitus, or gall bladder abnormalities. * History of alcohol or drug dependency. * Clinically diagnosed psychiatric disorder. * Currently a participant or have been a participant in any other study involving an investigational product within the last 4 weeks. * Received a COVID-19 diagnosis within the last 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease

Contacts and locations

Locations

  • Norwich and Norfolk University Hospital Clinical Research Facility

    Norwich, Norfolk, NR4 7UY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.